Diagnostic procedures for Parkinson's disease dementia: Recommendations from the Movement Disorder Society Task Force

被引:804
作者
Dubois, Bruno [1 ]
Burn, David [2 ]
Goetz, Christopher [3 ]
Aarsland, Dag [4 ,5 ]
Brown, Richard G. [6 ,7 ]
Broe, Gerald A. [8 ,9 ]
Dickson, Dennis [10 ]
Duyckaerts, Charles [11 ]
Cummings, Jefferey [12 ]
Gauthier, Serge [13 ]
Korczyn, Amos [14 ]
Lees, Andrew [15 ]
Levy, Richard [16 ,17 ]
Litvan, Irene [18 ]
Mizuno, Yoshikuni [19 ]
McKeith, Ian G. [20 ]
Olanow, C. Warren [21 ,27 ]
Poewe, Werner [22 ]
Sampaio, Cristina [23 ,24 ]
Tolosa, Eduardo [25 ]
Emre, Murat [26 ]
机构
[1] Univ Paris 06, Salpetriere Hosp, APHP, INSERM UPMC UMRS 610, Paris, France
[2] Univ Newcastle, Inst Ageing & Hlth, Newcastle Upon Tyne, Tyne & Wear, England
[3] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA
[4] Stavanger Univ Hos, Norwegian Ctr Movement Disorders, Stavanger, Norway
[5] Univ Bergen, Sch Med, N-5020 Bergen, Norway
[6] Kings Coll London, Dept Psychol, London WC2R 2LS, England
[7] Kings Coll London, Inst Psychiat, MRC Ctr Neurodegenerat Res, London WC2R 2LS, England
[8] Prince Wales Hosp, Ageing Res Ctr, Randwick, NSW 2031, Australia
[9] Univ New S Wales, Prince Wales Med Res Inst, Fac Med, Randwick, NSW, Australia
[10] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA
[11] Univ Paris 06, Salpetriere Hosp, Neuropathol Lab, INSERM,U679, Paris, France
[12] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90024 USA
[13] McGill Ctr Studies Aging, Alzheimer Dis & Related Disorders Unit, Montreal, PQ, Canada
[14] Tel Aviv Univ, Dept Neurol, Ramat Aviv, Israel
[15] Natl Hosp Neurol & Neurosurg, Dept Neurol, London WC1N 3BG, England
[16] Hop St Antoine, AP HP, Serv Neurol, F-75571 Paris, France
[17] Salpetriere Hosp, INSERM, U610, F-75013 Paris, France
[18] Univ Louisville, Sch Med, Dept Neurol, Movement Disorder Program, Louisville, KY 40292 USA
[19] Juntendo Univ, Sch Med, Dept Neurol, Res Inst Dis Old Ages,Bunkyo Ku, Tokyo 113, Japan
[20] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[21] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA
[22] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[23] Fac Med Lisbon, Lab Farmacol Clin & Terapeut, Lisbon, Portugal
[24] Inst Mol Med, Lisbon, Portugal
[25] Univ Barcelona, CIBERNED, IDIBAPS,Parkinsons Dis & Movement Disorders Unit, Hosp Clin Barcelona,Inst Clin Neurosci,Neurol Ser, Barcelona, Catalonia, Spain
[26] Istanbul Univ, Istanbul Fac Med, Behav Neurol & Movement Disorders Unit, Dept Neurol, Istanbul, Turkey
[27] Mt Sinai Sch Med, Dept Neurol, New York, NY USA
基金
英国医学研究理事会;
关键词
Parkinson's disease; PD dementia; diagnostic criteria; executive functions; task force;
D O I
10.1002/mds.21844
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A preceding article described the clinical features of Parkinson's disease dementia (PD-D) and proposed clinical diagnostic criteria for "probable" and "possible" PD-D. The main focus of this article is to operationalize the diagnosis of PD-D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time-consuming. Level I can be used alone or in concert with Level 11, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD-D for clinical monitoring, research studies or pharmacological trials. Level 11 tests can also be proposed when the diagnosis of PD-D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence-based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. (c) 2007 Movement Disorder Society
引用
收藏
页码:2314 / 2324
页数:11
相关论文
共 74 条
  • [1] Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
    Aarsland, D.
    Emre, M.
    Lees, A.
    Poewe, W.
    Ballard, C.
    [J]. NEUROLOGY, 2007, 68 (01) : 80 - 80
  • [2] Aarsland D, 2001, INT J GERIATR PSYCH, V16, P184, DOI 10.1002/1099-1166(200102)16:2<184::AID-GPS304>3.0.CO
  • [3] 2-K
  • [4] Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress
    Aarsland, D.
    Bronnick, K.
    Ehrt, U.
    De Deyn, P. P.
    Tekin, S.
    Emre, M.
    Cummings, J. L.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (01) : 36 - 42
  • [5] Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO
  • [6] 2-8
  • [7] [Anonymous], 1994, Psychol Assess, DOI DOI 10.1037/1040-3590.6.2.129
  • [8] [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
  • [9] BENTON A L, 1981, Journal of Clinical Neuropsychology, V3, P33, DOI 10.1080/01688638108403111
  • [10] Benton A. L., 1983, MULTILINGUAL APHASIA